The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...

People with thyroid eye disease receiving infusions of the insulin-like growth factor-1 receptor veligrotug report improved ...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Despite falling consumption rates, Germany still ranks among the world’s heaviest drinking nations, with per capita intake ...

A Danish registry study finds no substantial differences in the 5-year risk for first cancers between three biologics in patients with psoriasis.

Insights from AANEM 2025, including anticipated presentations, key takeaways, and how emerging research in myasthenia gravis ...

GLP-1s can cause changes in hydration, nutrition, and GI function that directly affect the mouth. Aminoshariae said these ...

Dr Katherine Ruzhansky previews presentations on biomarkers, new therapies, and translational science at AANEM 2025.

Against Medical Advice’ discharge notes often include stigmatizing language, with providers expressing anger and judgment.

Researchers have developed a hydrogel that lasts longer than current treatments for vocal fold disorders and could reduce the ...

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against ...